
In the first quarter of fiscal 2022, Genmab has received USD 19.5m from sales of multiple sclerosis drug Kesimpta, which has been licensed to Swiss firm Novartis.
Genmab is behind the active ingredient, ofatumumab, in Novartis’ Kesimpta, and the Danish biotech firm receives 10-percent royalties from Novartis’s sales.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app